Advertisement
News
Advertisement

ACT seeks orphan drug status in Europe for vision loss treatment

Thu, 12/23/2010 - 9:37am
Mass High Tech: The Journal of New England Technology

Advanced Cell Technology (ACT) Inc. has filed in Europe for Orphan Drug Designation for its retinal epithelial (RPE) cells to treat Stargardt’s Macular Dystrophy (Stargardt’s Disease), according to a news release today.

If the treatment is approved by the European Medicines Agency, ACT would secure 10 years of marketing exclusivity for RPE cells taken from embryonic stem cells, certain fee reductions or waivers and free scientific advice.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading